JOURNAL OF PERIODONTOLOGY, cilt.74, sa.9, ss.1348-1354, 2003 (SCI-Expanded)
Background: The present study was designed to assess histopathologically whether the systemic administration of aminobisphosphonate (alendronate), 0.5 mg/kg body weight, is effective in preventing alveolar bone resorption following mucoperiosteal flap surgery, and whether alendronate modulates tissue factors.